| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 0 | 0 | 28 | 263 | 705 | 13 | 0 | 94 | 59 | 11 |
| Total Expenses - EUR | 1.830 | 1.130 | 1.327 | 1.045 | 343 | 135 | 604 | 278 | 188 | 73 |
| Gross Profit/Loss - EUR | -1.830 | -1.130 | -1.299 | -782 | 363 | -121 | -604 | -185 | -128 | -63 |
| Net Profit/Loss - EUR | -1.830 | -1.130 | -1.299 | -788 | 322 | -121 | -585 | -185 | -128 | -63 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Ambamed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.754 | 1.824 | 906 | 163 | 160 | 157 | 0 | 0 | 0 | 0 |
| Current Assets | 70 | 86 | 98 | 52 | 553 | 456 | 76 | 221 | 1.123 | 1.053 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 31 | 52 | 70 | 52 | 64 | 67 | 76 | 79 | 92 | 99 |
| Cash | 39 | 34 | 28 | 0 | 488 | 389 | 0 | 142 | 1.031 | 954 |
| Shareholders Funds | -1.776 | -2.888 | -4.138 | -4.850 | -4.434 | -4.471 | -4.957 | -4.887 | -5.001 | -5.035 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 4.599 | 4.797 | 5.141 | 5.065 | 5.147 | 5.084 | 5.033 | 5.108 | 6.123 | 6.088 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
6820
|
|||||||||
Comments - Ambamed S.r.l.